A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience

Abstract

Background and Objective: Cancer survival has improved significantly, which reflects the achievements in screening, diagnosis, and treatment. As a consequence, multiple primary malignancies are diagnosed more frequently, with an incidence ranging from 0.52–11.7%. The types of malignancy that coexist and survival patterns vary notably in different countries and geographical areas. Due to the limited literature in Saudi Arabia, a baseline of prevalent malignancy combinations and their survival patterns would support early detection and disease management. Method: This was a retrospective descriptive study conducted from 1993–2022 at King Abdulaziz Medical City, Department of Medical Oncology, Riyadh, Saudi Arabia. Patients with at least two biopsy-proven solid malignancies were included. Patients with hematological malignancies, missing data, or an uncertain or indecisive pathology report were excluded. Result: In total, 321 patients were analyzed. More than half (57.3%) of the patients were female. A third (33%) of the cases were synchronous, and 67% were metachronous. The most frequent site of the first primary malignancy was breast cancer, followed by colorectal, skin, and thyroid cancers. The most frequent site of the second primary malignancy was colorectal cancer, followed by thyroid, breast, and liver cancers. Only 4% of the cases had a third primary malignancy, with colorectal and appendiceal cancers being the most frequent. The most frequently observed histopathology in the synchronous and metachronous malignancies was adenocarcinoma. Breast–colorectal, breast–thyroid, and kidney–colorectal were the most frequently observed malignancy combinations. Conclusion: The current study offers a baseline of multiple primary malignancies in Saudi Arabia and provides supporting evidence that the pattern of multiple primary malignancies varies among different countries and ethnicities. The possibility of developing another primary malignancy should be considered when treating and monitoring cancer patients.

Thrombocytosis as a paraneoplastic syndrome in metastatic malignant peritoneal mesothelioma of biphasic morphology mimicking ovarian adenocarcinoma: A case report

“…A metachronous malignancy is a second malignancy occurring at least 6 months after the first malignancy. 9 In this article, we report a rare case of metachronous diffuse malignant peritoneal mesothelioma mimicking ovarian adenocarcinoma with peritoneal metastasis.…”

A case report of synchronous triple primary malignancies: Diffuse large B-cell lymphoma, rectal adenocarcinoma and hepatocellular carcinoma

“…The study of this case may provide useful information regarding the diagnosis and treatment of patients with similar conditions. We concluded the following points ( 1 ): Clinicians must keep in mind that patients with multi-organ simultaneous lesions may suffer from MPM ( 2 ). We suggest a scrupulous biopsy of suspicious lesions in patient with multiple lesions of different organs to improve the diagnostic accuracy ( 3 ).…”

“…MPM are classified as synchronous when tumors are diagnosed within 6 months of each other, otherwise as metachronous ( 1 ). Metachronous presentation is more frequent than synchronous, with a ratio of about 2-4 ( 2 , 3 ). MPM mainly involve breast, lung, prostate, and melanoma.…”

Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study

“…Non-Hodgkin lymphoma (NHL) is the most common hematological malignancy, accounting for approximately 2.8% of new cancer cases and 2.6% of cancer-related deaths worldwide in 2020 [1][2][3]. Advances in screening, prevention, diagnosis, and therapeutics have significantly increased the life expectancy and survival of cancer patients, which also increases the risk of developing second primary malignancies (SPMs) [4]. Previous evidence suggests a significant increase in the risk of SPM including NHL after NHL due to improved survival in recent years [5,6], which has gradually become an important cause of mortality in addition to primary tumors [7].…”